Insulin normalization as an approach to the pharmacological treatment of obesity.

摘要: Hyperinsulinemia and exaggerated insulin response to glucose are among the hallmarks of obesity. However, role hyperinsulinemia in etiology maintenance obesity has been controversial. If plays a critical as proposed, then its reversal may have therapeutic potential. To test this hypothesis, activity Ro 23-7637, (4-(2,2-diphenylethenyl)-1-[1-oxo-9-(3-pyridinyl) nonyl]piperidine), which partially normalizes plasma by an action on pancreatic islets from obese rats, was assessed. When were cultured for 2 days with 10 microM significant reduction glucose-induced secretion observed. lean rats exposed no The effects oral administration 23-7637 assessed Zucker diet-induced doses ranging 5 90 mg/kg/day. Dose-related reductions observed in: 1) secretion; 2) basal concentration; 3) daily food intake; 4) bodyweight gain. In selective mobilization fat, body protein, decreased energetic efficiency also An association between partial normalization responses insulin, reduced rates weight gain or loss intake rats. Therefore, these studies indicate that is orally active, efficacious antiobesity agent.